TECHNE CORPORATION ANNOUNCES ACQUISITION COMPLETION

Minneapolis - July 22, 2013 - Techne Corporation (NASDAQ: TECH) (Techne)
announced today that it has finalized its previously announced acquisition of
Bionostics Holdings Limited and its operating subsidiary Bionostics, Inc.
(Bionostics). Bionostics was acquired for approximately $104 million in cash,
subject to adjustments following closing based on the final level of working
capital.

Bionostics is a global leader in the development, manufacture and
distribution of control solutions that verify the proper operation of in
vitro diagnostic (IVD) devices primarily utilized in point of care blood
glucose and blood gas testing.  Bionostics has strategic supply relationships
with virtually all global IVD device Original Equipment Manufacturers (OEMs).

Techne, through its subsidiaries R&D Systems and R&D Systems Europe, is
engaged in the development, manufacture and sale of biotechnology products
and hematology calibrators and controls.  Bionostics and Techne's Hematology
Division will collectively operate under a new Clinical Controls Division of
R&D Systems after close of the transaction.

Bionostics was founded in 1981 and is based in Devens, Massachusetts.  Its
controls are proprietary device-specific formulations which require FDA
510(k) approval.  Like the products made by R&D Systems' Clinical Controls
Division, each control is also a component of the OEM's 510(k), making
Bionostics' controls integral to each diagnostic device.  Controls for blood
glucose and blood gas devices are the largest portion of Bionostics'
business.  Bionostics recently launched coagulation device control products
and is developing new controls for other growing diagnostic uses,
particularly controls for cholesterol and HbA1c point-of-care testing (POCT)
devices.

Fredrikson & Byron, P.A. served as legal counsel to Techne.

-----------------------------------------

TECHNE Corporation and Subsidiaries (the Company) are engaged in the
development, manufacture and sale of biotechnology products and hematology
calibrators and controls. These activities are conducted through the
Company's two operating subsidiaries: Research and Diagnostic Systems, Inc.
(R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D
Europe) of Abingdon, England. R&D Systems is a specialty manufacturer of
biological products. R&D Systems has three subsidiaries: BiosPacific, Inc.
(BiosPacific), located in Emeryville, California, Boston Biochem, Inc.,
located in Cambridge, Massachusetts, and R&D Systems China Co. Ltd., (R&D
China), located in Shanghai, China. BiosPacific is a worldwide supplier of
biologics to manufacturers of in vitro diagnostic systems and
immunodiagnostic kits. Boston Biochem is a leading developer and manufacturer
of ubiquitin-related research products. R&D China and R&D Europe distribute
biotechnology products. R&D Europe has two subsidiaries: Tocris Holdings Ltd.
(Tocris) of Bristol, England and R&D Systems GmbH, a German sales operation.
Tocris is a leading supplier of chemical reagents for non-clinical life
science research.

Contact:   Greg Melsen, Chief Financial Officer
           Kathy Backes, Controller
           (612) 379-8854